Theravance Biopharma's total assets for Q3 2025 were $415.46M, a decrease of -2.48% from the previous quarter. TBPH total liabilities were $182.78M for the fiscal quarter, a -9.15% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.